Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

89.76 +0.53 (+0.59%)
Official Closing Price Updated: 4:10 PM EDT, Mar 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
81 82 Next >
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9. 
Via Investor's Business Daily
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.
Via The Motley Fool
Topics Intellectual Property Retirement
Exposures Intellectual Property Pension
What's going on in today's session: S&P500 movers
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Which S&P500 stocks are moving on Friday?
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Which Dow Jones Stock Is Cheaper, Amgen or Merck?
Via The Motley Fool
Topics Intellectual Property Stocks
Exposures Intellectual Property US Equities
Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares?
The FDA is due to make an approval decision in mid-September for a key product from the top pharma company. 
Via Investor's Business Daily
Exposures Product Safety
Is Merck Stock a Bargain Buy?
Via The Motley Fool
Gamestop, FST Corp, Merck, UPS, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
The U.S. stock market had a mixed session on Tuesday. The Nasdaq Composite climbed nearly 80 points, or 0.5%, closing at 18,271.86, while the Dow remained largely flat at 42,587.50. The S&P 500 edged... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
Via The Motley Fool
What's going on in today's session: S&P500 movers
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday. 
Via Chartmill
Tuesday's session: top gainers and losers in the S&P500 index
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday. 
Via Chartmill
Merck Enters $2B License Agreement With China-Based Hengrui Pharma For Heart Disease Drug: Retail’s Unswayed
The Chinese company will receive $200 million upfront and will be eligible to earn up to $1.77 billion in milestone payments and royalties on net sales of the drug, if approved. 
Via Stocktwits
Merck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment
Merck secures global rights to HRS-5346, an investigational Lp(a) inhibitor, in a deal with Hengrui Pharma worth up to $1.97 billion. 
Via Benzinga
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges
Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials for melanoma continue into 2025. 
Via Benzinga
Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics
Summit Therapeutics' ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the $100B VEGF x PD-(L)1 space. 
Via Benzinga
Which S&P500 stocks are gapping on Monday?
Curious about the S&P500 stocks that are gapping on Monday? Explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
1 Value Stock with Solid Fundamentals and 2 to Turn Down
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
2 Beaten-Down Stocks to Buy on the Dip
Via The Motley Fool
“We’re In A Stock Pickers Market”
Markets have been oscillating up and down for weeks, creating what resembles a sine wave pattern. As the analyst notes, 
Via Talk Markets
Topics ETFs
Which Is The Healthiest Investment: Merck Or Pfizer
Adeep dive into Merck and Pfizer, two of the biggest pharmaceutical companies out there. 
Via Talk Markets
Topics Stocks / Equities
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
Merck & Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types
Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested in its Phase 1 trial. 
Via Benzinga
Why MERCK & CO. INC. (NYSE:MRK) qualifies as a good dividend investing stock.
Balancing Dividends and Fundamentals: The Case of MERCK & CO. INC. (NYSE:MRK). 
Via Chartmill
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks
Exposures US Equities
A Closer Look at Merck & Co's Options Market Dynamics
Via Benzinga
These S&P500 stocks are gapping in today's session
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Friday and stay ahead of the market trends. 
Via Chartmill
Inflation Isn’t Going Away, But These Sectors Don’t Care
The CPI and PPI releases this week came in more or less at estimates - nothing to alarm the talking heads, anyway. They show inflation slowing down but not receding. 
Via Talk Markets
Topics ETFs Economy Stocks / Equities
Exposures Interest Rates
How Do Investors Really Feel About Merck & Co?
Via Benzinga
Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025
Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for mid-2025. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
81 82 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.